Share ownership Beam Therapeutics Inc.

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
26.52 ^USD	+7.24%		-3.98%	-4.33%

02-05	Beam Therapeutics Inc. Announces Resignation of Carole Ho from the Board of Directors, Effective February 27, 2026	CI
01-14	Beam Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM

Share class: Beam Therapeutics Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	82,805,627	81,633,998 ( 98.59 %)	0	98.59 %

Major shareholders: Beam Therapeutics Inc.

Name	Equities	%	Valuation
ARK Investment Management LLC 12.29 %	12,467,189	12.29 %	344 M $
Fidelity Management & Research Co. LLC 11.52 %	11,692,853	11.52 %	323 M $
ARK Investment Management LLC 10.88 %	11,038,834	10.88 %	305 M $
Farallon Capital Management LLC 9.917 %	10,063,111	9.917 %	278 M $
Vanguard Fiduciary Trust Co. 9.06 %	9,193,474	9.06 %	254 M $
BlackRock Advisors LLC 7.365 %	7,473,187	7.365 %	206 M $
Amova Asset Management Americas, Inc. 4.761 %	4,830,738	4.761 %	133 M $
ARCH Venture Partners LLC 4.474 %	4,540,132	4.474 %	125 M $
SUMITOMO MITSUI TRUST GROUP, INC. 4.345 %	4,409,300	4.345 %	122 M $
STATE STREET CORPORATION 3.95 %	4,008,658	3.95 %	111 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	102.26%
Other	6.63%
Sumitomo Mitsui Trust Group, Inc.	4.35%
State Street Corp.	3.95%
Individuals	1.66%
Alphabet, Inc.	0.32%
Schweizerische Nationalbank	0.17%
Manulife Financial Corp.	0.14%
SEI Investments Co.	0.04%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	95.28%
United Kingdom	8.63%
Japan	4.36%
Switzerland	4.19%
Individuals	1.66%
Australia	1.64%
Bermuda	1.51%
Ireland	0.86%
Canada	0.59%
China	0.18%
Germany	0.15%
Denmark	0.11%
France	0.07%
Netherlands	0.07%
Austria	0.06%
Hong Kong	0.05%
Poland	0.04%
Sweden	0.03%
Norway	0.02%
Luxembourg	0.02%

Based on 1000 largest holdings

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Employees

510

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company